Wetzel brings over 15 years of experience, offering a unique 360-degree perspective of the healthcare and life sciences industries. Wetzel has held senior legal and compliance positions at a multinational manufacturer of medical devices, and served as Deputy General Counsel of AdvaMed, the medical technology trade association based in Washington, D.C. Most recently, Wetzel launched the global compliance and risk management program at Silicon Valley-based biotech startup GRAIL.
“We are thrilled to add depth to our premier, full-service practices in support of two industries facing unprecedented disruption set against an evolving regulatory landscape,” said David Cappillo, co-chair of Goodwin’s Healthcare practice. “Matt has sat in our clients’ seats, and his deep experience in the medical technology industry allows him to truly understand the opportunities and challenges our clients face. His strong compliance, transactional, and regulatory experience provides a significant advantage to the innovators and investors in the healthcare services and technology, and life sciences sectors.”
Wetzel advises clients on a variety of healthcare legal and regulatory matters, including guidance on federal and state healthcare fraud and abuse laws, billing and reimbursement requirements, and transparency requirements, among other areas. He works with clients to build, manage, and grow internal compliance and risk management programs, including conducting third-party risk assessments and internal investigations, and developing policies and training. Wetzel also provides corporate support on transactions; support on government enforcement actions or other healthcare-related disputes; and other regulatory guidance on healthcare-related matters.
Over the past year, Goodwin’s Healthcare and Life Sciences practices continued to rank highly in global league tables. Mergermarket’s latest Deal Drivers reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America and the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa. Pitchbook’s latest full-year league tables named Goodwin the number three most active in global venture capital deals for pharma and biotech, the number four most active in global private equity — healthcare deals, and the number four most active in global venture capital deals for healthcare devices, supplies, services, and systems.